In vitro and in vivo studies of a newly synthesized copper-cetyl tri-methyl ammonium bromide combined with gallium oxide nanoparticles complex as an antitumor agent against hepatocellular carcinoma

Abstract

Objective: Hepatocellular carcinoma (HCC) is one of the most leading causes of death worldwide. Previous studies reported that gallium alone and cetyltrimethylammonium bromide (CTAB) have antineoplastic activities; therefore, this study aimed to evaluate the activity of copper‐cetyl tri‐methyl ammonium bromide with gallium oxide nanoparticles (Cu‐CTAB+GaO‐NPs) against HCC by using in vitro and in vivo studies. Methods: In vitro study was performed to evaluate the cytotoxic effects of Cu‐CTAB+GaO‐NPs and GaO‐NPs on HepG‐2 cell line using crystal violet dye assay. In vivo study was done on diethyl nitrosamine (DEN) induced HCC Wister rats. Rats were randomly divided into eight groups; control, Cu‐CTAB, GaO‐NPs, Cu‐CTAB+GaONPs, DEN, DEN+Cu‐CTAB, DEN+GaO‐NPs and DEN+Cu‐CTAB+GaO‐NPs. Histopathological examination of liver and biochemical parameters such as liver function markers, oxidative stress-antioxidants markers, tumor makers, apoptosis makers were studied. Results: Results obtained from in vitro study revealed that Cu‐CTAB+GaO‐NPs and GaO‐NPs affect the cell viability of HepG‐2 cancer cell with IC50 0.2 μg/ml and 360 μg/ml, respectively. Cu‐CTAB+GaO‐NPs exerted an antiproliferative effect in experimental rat models of HCC, as demonstrated both histologically, since it facilitated the tissue recovery of the damaged liver, and biochemically as showed by the reduction of liver function markers (ALT & AST), oxidative stress markers (MDA) and tumor makers (AFP,TGF‐β1,α‐L–Fucosidase); while antioxidants markers (SOD), apoptosis markers (caspase‐3 mRNA) and araginase activity were elevated in DEN+Cu‐CTAB, DEN+GaO‐NPs and DEN+Cu‐CTAB+GaO‐NPs groups when compared to DEN group. Conclusion: The present study demonstrated that both Cu‐CTAB alone and/or combined with GaO‐NPs exerted cytotoxic effects against DEN-induced HCC, which would in turn, speculate a possible therapeutic role of the novel Cu‐CTAB+GaO‐NPs compound.

Graphical Abstract

Keywords

Hepatocellular carcinoma Nanoparticles Nanomedicine Diethyl nitrosamine Gallium oxide nanoparticles Cetrimonium bromide

Introduction

Based on global cancer statistics in 2020, liver cancer is one of the most common cancers, reported as the sixth most common of all cancer incidents and the fourth leading cause of cancer-related deaths in the world.¹ Risk factors that can cause or increase the probability of liver cancer incidence include hepatitis B or C virus (HBV or HCV) infections, aflatoxin exposures, obesity, type 2 diabetes mellitus, heavy alcohol drinking, and tobacco smoking.² There are an increasing number of experimental mouse models used in liver cancer research to investigate its pathogenesis and assess novel therapeutics. For several decades, the most widely used chemical to induce liver cancer in mice is diethylnitrosamine (DEN), which targets the liver where it is metabolically activated by centrilobular hepatocytes into alkylating agents that can form mutagenic DNA adducts and finally can result in the development of cancer.³

Due to the limitations and problems of conventional pharmaceutical agents, the nanotechnology has a significant role in the field of medicine and drug delivery, has come to be called “nanomedicine”. ⁴ Gallium is a metal of atomic number 31 in group IIIA in the periodic table of elements, presents at a concentration of 5–15 mg/kg in the earth’s crust, and obtains during the extraction of aluminum and zinc ores as a byproduct.⁵ The chemical features of the Ga³⁺ ion and its ability to interfere with numerous cellular functions, such as apoptosis, DNA replication, and repair, made this metal very attractive for biomedical scientists, paving the way to several therapeutic applications.⁶ The therapeutic properties of gallium led to the development of novel formulations for the treatment of various disorders in humans, including cancer, autoimmune diseases, accelerated bone resorption, and infectious diseases. Numerous studies reported that gallium has several diagnostic and therapeutic applications as it has antineoplastic,^7–9 antibacterial,^10–12 antifungal,¹³ immunosuppressive, and anti-inflammatory activities.^14,15 Moreover, radioactive gallium (⁶⁷Ga citrate) was found to be localized in malignant cells and therefore ⁶⁷Ga scan used for the detection of malignant tumors in patients.¹⁶

Cetrimonium bromide ([(C16H33)N(CH3)3]Br; cetyl tri-methyl ammonium bromide; hexadecyltrimethylammonium bromide; CTAB) is a quaternary ammonium surfactant used as a topical antiseptic and has a tremendous inhibitory effect on osteosarcoma and therefore may play a variety of roles in cancer treatment.¹⁷

Therefore, the present study was conducted to evaluate the efficiency of the novel compound copper-cetyl tri-methyl ammonium bromide combined with gallium oxide nanoparticle complex (Cu-CTAB + GaO-NPs) to reduce the incidence of hepatocellular carcinoma. The work comprises both in vivo and in vitro studies. The in vitro cytotoxic effect of this compound has been investigated using human hepatocellular carcinoma (HepG-2) cell line. The compounds were further promoted into in vivo studies, using DEN-induced liver tumors in the male rat model, to validate whether the novel complex (Cu-CTAB + GaO-NPs) could be used as a promising strategy for liver cancer therapy.

Methods

As mentioned above, this study was aimed to evaluate the ameliorative effect of Cu-CTAB + GaO-NPs against hepatocellular carcinoma induced by DEN in rats. The next paragraphs will describe chemicals and in vivo and in vitro studies used.

Chemicals

Diethyl nitrosamine, cetyl tri-methyl ammonium bromide, copper dichloride, and gallium oxide were obtained from Sigma Aldrich Chemical Co., St. Louis, Mo., USA. All these chemicals and reagents used were of analytical grade. Assay kits for testing alanine aminotransferase (ALT), aspartate transaminase (AST), total protein, iron concentration, and α-l–fucosidase were supplied by Biodiagnostics (Egypt). ELISA Kits for alpha-fetoprotein (AFP), transforming growth factor-β1 (TGF-β1), and caspase 3 (casp-3) were obtained from Cusabio Biotech, China; Elabscience, China; and MyBioSource, USA; respectively.

Experimental animals

Adult (20 weeks old) male Wister rats weighing about 140 ± 20 gm were obtained from the Nile Pharmaceutical Co., Cairo, Egypt. The animals were kept under standard laboratory conditions of light/dark cycle (12/12 h), a temperature of 25 ± 2°C and humidity of 60 ± 5%, and were housed in cages with free access to food and drinking water. Animals were fed on standard pellet diet, and sterilized water was provided ad libitum. All animal procedures were carried out in accordance with the Ethics Committee of The National Center for Radiation Research and Technology in accordance with the “Guide for the Care and Use of Laboratory Animals” published by the US National Institute of Health (NIH publication, No. 85-23, 1996).

Methods

Chemical studies

Synthesis of cetyl tri-methyl ammonium bromide copper complex

Cetyl tri-methyl ammonium bromide (CTAB) was synthesized according to Badawi et al.¹⁸ Firstly, CTAB was prepared by refluxing 2 M amounts of the cationic surfactant (CTAB) and 1 mole of copper dichloride (CuCl₂) in ethanol for 6 h. Then, the resultant crystals were washed twice with petroleum ether and recrystallized from methanol, and finally dried under vacuum at 50°C for 4 h.

Synthesis of gallium oxide nanoparticles

Nanoparticles of gallium oxide (GaO-NPs) were prepared by grinding gallium oxide powder to the nano-sized particles using ball mill at 200 r/min for 8 h and then suspended by mixing 0.25 gm of gallium oxide nanoparticles with 100 mL of distilled water using ultra-sonication for 30 min.

Synthesis of Cu-CTAB + GaO-NP complex

The newly synthesized Cu-CTAB + GaO-NP complex was prepared by suspending 0.25 gm of gallium oxide nanoparticles in 3 gm of Cu-CTAB complex dissolved in 100 mL distilled water using ultra-sonication for 30 min and then the characterization of complex was detected by using transmission electron microscopy (TEM) to determine size and morphology.

Characterization of Cu-CTAB + GaO-NP complex

To ensure that the new synthesized Cu-CTAB + GaO-NP complex was in nanoscale and to study its physicochemical properties, a panel of analyses was conducted at the Nanotechnology Unit, Egyptian Petroleum Institute (Egypt), for nano-verification of the novel Cu-CTAB + GaO-NP complex, which are as follows:

Transmission electron microscopy (TEM)

A sample for transmission electron microscopy (TEM) of the synthesized Cu-CTAB + GaO-NP was prepared by placing a drop of it on carbon-coated copper grids and allowing water to evaporate. The shape and size of complex were determined from TEM micrographs. The software (Advanced Microscopy Techniques, Danvers, MA) for the digital TEM camera was calibrated for size measurements of the nanoparticles according to Gurunathan et al.,¹⁹ while the spectrum absorbance of Cu-CTAB + GaO-NPs was analyzed by using ultraviolet-visible (UV-Vis) spectroscopy (JASCO UV-Vis spectrophotometer model V-750) in a measurement range of 200–600 nm. Then, a sample of Cu-CTAB + GaO-NPs was analyzed for size distribution throughout dynamic light scattering (DLS) by photon correlation spectroscopy using a Zetasizer ZS instrument (Malvern Instruments Ltd., Malvern, UK).

Evaluation of therapeutic antitumor efficacy of biosynthesized Cu-CTAB + GaO-NP complex

The present study was designed to comprise a series of in vitro and in vivo investigations as following:

In vitro study

The antitumor effects of Cu-CTAB, GaO-NPs, and combination of them were investigated on the viability of the human liver cancer cell line (HepG-2) using cell viability assay by crystal violet staining method.

In vivo study

Determination of the Median Lethal Dose (LD₅₀)

To evaluate the LD50 of the synthesized compounds (Cu-CTAB combined with GaO-NPs and GaO-NPs alone), ascending oral doses of the novel tested complex (Cu-CTAB + GaO-NPs) and gallium oxide nanoparticles (GaO-NPs) were administered into male Wister rats (6 rats/group) weighing about 120–150 gm. Mortality incidence was recorded 24 h after administration. The optimum selected dose for evaluating the in vivo antitumor activity of the novel synthesized composite and gallium oxide nanoparticles alone was calculated approximately as (1/10) of their LD₅₀ values, whereas LD₅₀ of Cu-CTAB was reviewed in previous literature.¹⁸

Biochemical studies

Experimental Design:

Eighty Wister rats weighing 120–150 gm were equally divided randomly into the following eight groups:

• Group 1 (control): Untreated control group of healthy rats.

• Group 2 (Cu-CTAB): Rats received 6.5 mg/kg body weight of Cu-CTAB orally five times per week for 4 weeks, according to Badawi et al.¹⁸

• Group 3 (GaO-NPs): Rats were treated orally with GaO-NPs (3.3 mg/kg b. w.) five times per week for 4 weeks by intragastric gavage, according to Abdalla et al.²⁰

• Group 4 (Cu-CTAB + GaO-NPs): Rats received 16.3 mg/kg b. w. of complex orally (five times per week) for 4 weeks.

• Group 5 (DEN): Rats received 20 mg/kg b. w. of DEN orally (five times per week for 6 weeks) and left alive for 4 weeks, according to Darwish and EL-Boghdady.²¹

• Group 6 (DEN + Cu-CTAB): Rats received DEN as in group 5 and then were administrated Cu-CTAB orally five times per week for 4 weeks as in group 2.

• Group 7 (DEN + GaO-NPs): Rats received DEN as in group 5 and then were treated with GaO-NPs orally five times per week for 4 weeks as in group 3.

• Group 8 (DEN + complex): After rats received DEN as in group 5, they were treated with tested complex orally five times per week for 4 weeks.

Twenty-four hours after the last treatment, all rats were anesthetized with the recommended anesthetic dose of urethane (1.15 g/kg)²² through intraperitoneal injection and then scarified and blood samples were obtained via heart puncture and collected in plain vacutainer tubes. Then samples were left to coagulate and serum was obtained after centrifuged at 4,000 rpm for 10 min for biochemical analysis. Liver was excised from animals in all groups. Part of the collected livers was homogenized (10% w/v) in phosphate-buffered saline (0.02 M sodium phosphate buffer with 0.15 M sodium chloride, pH 7.4) using glass homogenizer producing homogenates which were used for biochemical and molecular analyses, and the other part was quickly rinsed in saline solution and then kept in 10% formalin for histopathological examination.

Biochemical investigations

The activities of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and the concentrations of iron and total protein in the serum were measured calorimetrically using commercial assay kits (Biodiagnostic, Egypt) according to the manufacturer’s instructions.

The concentrations of alpha-fetoprotein (AFP) and transforming growth factor-β1 (TGF-β1) in serum were measured by using commercial sandwich ELISA Kit (Cusabio Biotech, China and Elabscience, China, respectively) according to the manufacturer’s instructions. While serum α-L–fucosidase activity was measured calorimetrically using commercial assay kits (Biodiagnostic, Egypt) according to the manufacturer’s instructions.

Lipid peroxidation was measured in the plasma and liver tissue homogenate according to the method of Yoshioka et al.,²³ and total thiobarbituric acid reactive substances (TBARS) were expressed as malondialdehyde (MDA). In brief, liver homogenates (10% w/v) were mixed with 10% TCA (ice cold), centrifuged at 800 g for 10 min, then the supernatant was mixed with thiobarbituric acid (TBA) to develop the color, boiled for 10 min at 100°C, cooled at room temperature, and finally optical density was read at 535 nm. Also, the activity of superoxide dismutase (SOD) in the red blood corpuscles and liver tissue and the activity of arginase in the liver tissue were determined calorimetrically using commercial assay kits (BioVision, USA) according to the manufacturer’s instructions.

Detection of caspase-3 by quantitative real time PCR (qRT-PCR)

Isolation of RNA from the liver of the studied groups was taken place after homogenization in TRIzol ® (Invitrogen) according to manufacturers’ protocol. For real-time PCR, reverse transcription of the extracted RNA samples was performed using a Superscript kit from Invitrogen. Real time PCR was performed using a Step One Plus™ sequence detection system from Applied Biosystems (Germany) with primer detecting and 2X Maxima® SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, USA). The qPCR cycling conditions were as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. The primer sequences are listed in Table 1. The relative expression of caspase-3 was normalized to β-actin expression and calculated according to the 2-ΔΔCq method described by Livak and Schmittgen.²⁴ A 2-fold increased (≥2) or decreased (≤0.5) value was considered mRNA overexpression or down regulation, respectively.

Table 1.

Primer sequences for quantitative RT-PCR analysis.

Gene	Primer sequence
Caspase-3	F: 5′- CAAACCACCAAGTGGAGGAG-3′
Caspase-3	R: 5′- GTGGGTGAGGAGCACGTAGT-3′
β-actin	F: 5′-ATTGTTACCAACTGGGACGACATG-3′
β-actin	R: 5′- GAAGTCTA GAGCAACATAGCACA-3′

Histopathological examination

Following rat sacrificing, the liver was rapidly dissected, excised, and rinsed in saline solution and then fixed in 10% formalin solution for at least 3 days at 4°C. Following fixation, the specimens were dehydrated in ascending series of alcohol (70% methyl, 70% ethyl, and absolute (95–100%) ethyl), cleared in xylene and then embedded in paraffin at 60°C. Sections of 5 microns thickness were cut and stained with hematoxylin and eosin and examined by using a light microscope.

Statistical analysis

Statistical analysis was performed using IBM SPSS software (version 23.0; IBM Corp., Armonk, NY, USA), and data were presented as means ± SE. Data were analyzed with one-way analysis of variance (ANOVA) followed by post hoc test (LSD) for multiple comparisons. The criterion for significance was p < 0.05.

Results

Characterization of gallium oxide nanoparticles combined with tetrahalocuprate complex

The prepared gallium oxide nanoparticles combined with tetrahalocuprate complex were characterized by using transmission electron microscopy (TEM) to determine their size and morphology. The images obtained from TEM showed that the sample of complex appeared as regular spheres and distributed homogeneously (Figure 1(a)). The formation of Cu-CTAB + GaO-NPs was confirmed by UV–visible spectroscopy with a sharp peak of maximum absorbance at 265 nm, indicating the synthesis of Cu-CTAB + GaO-NPs (Figure 1(b)). Finally, DLS measurement of the hydrodynamic effective diameter of the synthesized Cu-CTAB + GaO-NPs showed that the zeta average diameter was measured to be 127.2 nm with 0.957 poly dispersity index (PDI) indicating the homogeneity and uniform dispersion of the synthesized BAs-ZnNPs (Figure 1(c)).

Figure 1.

Characterization of Cu-CTAB + GaO-NP complex. (a): Transmission electron microscopic image of Cu-CTAB + GaO-NPs; (b): UV absorbance of Cu-CTAB + GaO-NPs; (c): dynamic light scattering of Cu-CTAB + GaO-NP complex.

In vitro study (cell viability tests)

The in vitro anticancer cytotoxic activities of complex (Cu-CTAB-GaO-NPs) and gallium oxide nanoparticles (GaO-NPs) alone were investigated on hepatocellular carcinoma human cell line (HepG-2) using crystal violet dye. The cytotoxic activity was expressed as reduction of cell viability relative to control. The 50% growth inhibitory concentration (IC₅₀) values were indicated in Figure 2 and Supplementary Tables S1, S3. The novel complex exhibited the strongest in vitro anticancer activity against HepG-2, as it recorded the lowest value (0.2 μg/ml) comparable to that of Cu-CTAB (11.07 μg/ml)¹⁸ and gallium oxide nanoparticles alone (360 μg/ml) against this hepatocellular carcinoma human cell line (HepG-2).

Figure 2.

Cell viability test. (a): Antitumor activity of Cu-CTAB combined with GaO-NPs against HepG-2 cell line; (b): antitumor activity of gallium oxide nanoparticles against HepG-2 cell line.

In vivo studies

Determination of median lethal dose (LD₅₀) value

The LD₅₀ of Cu-CTAB + GaO-NPs complex, Cu-CTAB, and GaO-NPs alone were 163 mg/kg b. w., 65 mg/kg b. w., and 33 mg/kg b. w., respectively.

Biochemical markers

Results of all estimated biochemical parameters are reported in Supplementary Table S3. Our results revealed that the activities of liver enzymes (ALT and AST) were significantly increased, but serum total protein concentration was significantly decreased in DEN-intoxicated rats when compared to control ones, while after administration of Cu-CTAB, GaO-NPs, or Cu-CTAB + GaO-NPs complex, the activities of liver enzymes (ALT and AST) were significantly decreased while serum total protein concentration was significantly increased in DEN + Cu-CTAB, DEN + GaO-NP, or DEN + Cu-CTAB + GaO-NP groups when compared to the DEN group, as shown in Figure 3.

Figure 3.

Liver function tests. (a): Serum ALT activity (U/L) in different groups; (b): serum AST activity (U/L) in different groups; (c): serum total protein concentration (g/dL) in different groups. Data are expressed as mean ± SE (n = 10). a: Significant compared to the control, b: significant compared to the Cu-CTAB group, c: significant compared to the GaO-NP group, d: significant compared to the Cu-CTAB + GaO-NP group, e: significant compared to the DEN group, (p < 0.05).

Also, results of the current study showed that the tumor markers such as serum AFP concentration and α-L–fucosidase activity were significantly decreased after the treatment with Cu-CTAB, GaO-NPs, or Cu-CTAB + GaO-NP complex in DEN + Cu-CTAB, DEN + GaO-NP, and DEN + Cu-CTAB + GaO-NP groups when compared to the DEN group, as shown in Figures 4(a),(c). Moreover, the concentration of TGF-β1 in serum was significantly decreased while serum iron concentration was significantly increased in DEN + Cu-CTAB, DEN + GaO-NP, or DEN + Cu-CTAB + GaO-NP groups when compared to the DEN group, as shown in Figures 4(b),(d).

Figure 4.

Serum tumor and inflammatory markers. (a): Serum AFP concentration (ng/mL) in different groups; (b): serum TGF-β1 concentration (pg/mL) in different groups; (c): serum α-L–fucosidase activity (U/L) in different groups; (d): serum iron concentration (μmol/L) in different groups. Data are expressed as mean ± SE (n = 10). a: Significant compared to the control, b: significant compared to the Cu-CTAB group, c: significant compared to the GaO-NP group, d: significant compared to the Cu-CTAB + GaO-NP group, e: significant compared to the DEN group, (p < 0.05).

Level of lipid peroxidation was evaluated by measuring the level of MDA either in liver tissues or plasma, while the antioxidant status was evaluated by measuring SOD activity either in liver tissues or RBCs. Our results showed that the level of MDA was significantly increased, and SOD activity was significantly decreased in the DEN group when compared to the control group. While after the treatment with Cu-CTAB, GaO-NPs, or Cu-CTAB + GaO-NPs complex in DEN + Cu-CTAB, DEN + GaO-NP, and DEN + Cu-CTAB + GaO-NP groups, the level of MDA was significantly decreased, while SOD activity was significantly increased when compared to the DEN group, as shown in Figure 5.

Figure 5.

Oxidative stress and antioxidant markers. (a): Level of MDA in liver tissues (blue color) (nmol/gm tissue) and plasma (red color) (nmol/L) in different groups; (b): activity of SOD in liver tissues (blue color) (U/gm tissue) and RBCs (red color) (U/mL) in different groups. Data are expressed as mean ± SE (n = 10). a: Significant compared to the control, b: significant compared to the Cu-CTAB group, c: significant compared to the GaO-NP group, d: significant compared to the Cu-CTAB + GaO-NP group, e: significant compared to the DEN group, (p < 0.05).

Results of the present study also showed that the activity of arginase and the level of caspase-3 mRNA in liver tissues were significantly increased in DEN + Cu-CTAB, DEN + GaO-NP, and DEN + Cu-CTAB + GaO-NP groups when compared to the DEN group, as shown in Figure 6.

Figure 6.

Liver mitotic and apoptotic markers. (a): Activity of arginase in liver tissues (U/gm tissue) in different groups; (b): activity of caspase-3 in liver tissues (U/gm tissue). Data are expressed as mean ± SE (n = 10). a: Significant compared to the control, b: significant compared to the Cu-CTAB group, c: significant compared to the GaO-NP group, d: significant compared to the Cu-CTAB + GaO-NP group, e: significant compared to the DEN group, (p < 0.05).

Histopathological findings

Histopathological examination was performed in the liver of all groups of animals that were investigated in the present study. Tissue specimens of the liver from control rats (Figure 7(a)) showed normal histological structure of the central vein and surrounding hepatocytes. Also, Cu-CTAB (Figure 7(b)), GaO-NPs (Figure 7(c)), and Cu-CTAB + GaO-NPs (Figure 7(d)) treated rats showed no histopathological alteration. By contrast, liver specimens from DEN-treated rats revealed severe damage of hepatocytes which was characterized by focal area of anaplastic hepatocytes with other cells forming acini associated with fibroblastic cell proliferation dividing the degenerated and necrosed hepatic parenchyma into nodules (Figure 7(e)). On the other hand, liver specimens from DEN + Cu-CTAB-treated rats showed degenerative change which was noticed in the hepatocytes adjacent and surrounding the dilated central vein (Figure 7(f)); while liver specimens from DEN + GaO-NP-treated rats showed inflammatory cell infiltration with fibroblastic cell proliferation dividing the degenerated hepatocytes into nodules in association with dilatation in the portal vein (Figure 7(g)). In DEN + Cu-CTAB + GaO-NP-treated rats, the degenerated hepatocytes in the parenchyma were divided into nodules by proliferated fibroblasts and inflammatory cell infiltration with dilated portal vein (Figure 7(h)).

Figure 7.

Photomicrograph of liver tissues of male rats of (a): the control group, showing normal histological structure of central vein (CV) and surrounding hepatocytes (h) (H&E, X40).; (b): the Cu-CTAB group, showing normal histological structure (H&E, X40); (c): the GaO-NP group, showing normal histological structure (H&E, X40); (d): the Cu-CTAB + GaO-NP group, showing normal histological structure (H&E, X40); (e): the DEN group, showing focal area of anaplastic hepatocytes with other cells forming acini (1) arrow (H&E, X40); (f): the DEN + Cu-CTAB group, showing dilatation in central vein (CV) with degeneration in surrounding adjacent hepatocytes (arrow) (H&E, X40); (g): the DEN + GaO-NPs group, showing fibrosis (f) with inflammatory cell infiltration (m) dividing the degenerated hepatocytes cells into nodules with dilatation in portal vein (PV) (H&E, X40); (H): the DEN + Cu-CTAB + GaO-NPs group, showing fibrosis (f) with inflammatory cell infiltration (m) dividing the degenerated hepatocytes (d) into nodules with dilatation in portal vein (PV) (H&E, X40).

Discussion

Hepatocellular carcinoma (HCC) is one of the most frequent malignancies and a leading cancer-related cause of death worldwide; therefore, there is an emergency need for improvements in the therapeutic approach during the last decades.²⁵ The present study was designed to synthesize and evaluate the activity of the novel complex Cu-CTAB + GaO-NPs against HCC. Accordingly, in the current study, the cytotoxic effects and the biological activities of complex (Cu-CTAB combined with GaO-NPs), Cu-CTAB, and GaO-NPs alone were evaluated both in vitro and in vivo.

Results obtained from in vitro study revealed that both tested complex and gallium oxide nanoparticles alone affect cell viability of HepG-2 cancer cell line with IC50 0.2 μg/mL and 360 μg/mL, respectively. These results are in harmony with early studies which observed the in vitro anticancer activity of gallium compounds against many cancer cell lines, including those for melanoma,²⁶ lymphoma,²⁷ colorectal adenocarcinoma,²⁸ breast carcinoma,²⁹ and hepatocellular carcinoma.³⁰ Also, the cytotoxicity effects of Cu-CTAB were determined on many cancer cell lines such as prostate cancer³¹ and osteosarcoma.¹⁷

In vivo experiments were estimated on male Wister rats, which were administrated diethyl nitrosamine (DEN) as a potent hepatocellular carcinogen and then treated with Cu-CTAB or/and GaO-NPs to evaluate the chemotherapeutic efficacy of the tested compounds against hepatocellular carcinoma. Several studies used DEN to induce hepatocellular carcinoma in an animal model, as it was found that DEN causes hepatic cellular injury through the generation of reactive oxygen species (ROS) and DNA damage.³² In this study, rats intoxicated with DEN showed a significant elevation in the activities of liver enzymes, ALT and AST, along with a significant decrease in the concentration of total proteins and severe histopathological liver deterioration, indicating the liver damage. These observations are consistent with previous studies, in which rats treated with DEN showed pronounced biochemical and histopathological hepatic fibrotic alterations.^33,34 Also, the results obtained from this study showed that rats intoxicated with DEN had a significant increase in the levels of MDA and a significant decrease in SOD activity as compared with the control group. Our results are in accordance with previous studies which reported that rat treatment with DEN caused oxidative stress as assigned by the increase in MDA and fall in SOD content.^32,35–38

In the present study, however, rats suffering from hepatocellular carcinoma treated with Cu-CTAB, GaO-NPs, and Cu-CTAB + GaO-NPs complex showed a significant decrease in serum activities of AST and ALT and the levels of MDA in liver and plasma while the concentration of serum total protein and SOD activity in the liver and RBCs were increased compared to the DEN-injected group. The obtained results may be attributed to the cytotoxicity of estimated compounds to tumor cells which resulted in diminished cellular damage and permeability of cell membrane, as consistent with previous studies.^6,39 Also, results of the current study revealed that the concentrations of serum AFP and TGF-β1 along with serum α–L–fucosidase activity were significantly decreased in rats treated with Cu-CTAB, GaO-NPs, and Cu-CTAB + GaO-NP complex when compared to the DEN-injected group, indicating the antitumor activity of Cu-CTAB, GaO-NPs, and Cu-CTAB + GaO-NP complex. Several studies reported the antitumor efficacy of Cu-CTAB^17,31 or GaO-NPs,^6,40 but this is the first study that showed the antitumor efficacy of Cu-CTAB + GaO-NP complex. The antitumor activity of gallium depends mainly on the mimic action of Ga³⁺ with Fe³⁺, and therefore gallium acts on cellular iron-dependent processes at various points to disrupt tumor growth.⁹ This explains the increased levels of serum iron in GaO-NP and Cu-CTAB + GaO-NP groups when compared to control or DEN + GaO-NP and DEN + Cu-CTAB + GaO-NP groups when compared to the DEN group. It was reported that gallium modifies DNA three-dimensional structure and modulates protein synthesis. Also, it inhibits the activity of several enzymes, such as DNA polymerases, ribonucleotide reductase, ATPases, and tyrosine-specific protein phosphatase.⁴¹ Schachter et al.⁴² documented that the high concentrations of CTAB displace phospholipids along the cell membrane, and formed holes cause the cell to be too permeable and to die, which may attribute to its antitumor activity. Another study reported that CTAB inhibited tumor formation and delayed tumor growth by inducing caspase-activated apoptosis by depolarization of the mitochondrial membrane potential and inhibition of H⁺-ATP synthase activity, therefore decreasing ATP levels in the cell.⁴³ In an agreement with our results, the levels of caspase-3 mRNA in liver tissues were significantly increased in rats treated with Cu-CTAB, GaO-NPs, and Cu-CTAB + GaO-NP complex when compared to the DEN-injected group, which emphasize their antitumor activities.

Arginase is a manganese-containing enzyme present mainly in the liver, and it catalyzes the final step in the urea cycle to get rid of toxic ammonia by converting L-arginine to L-ornithine and urea.⁴⁴ In the current study, the activity of arginase in all groups intoxicated with DEN had a significant decrease in respect to normal rats. Disorder of cellular metabolism is one of the critical marks for cancer production and expansion. Thus, the carcinogenic DEN decreases the arginase activity to prevent arginine deprivation because cancer cells need abnormal quantities of varied amino acids for their distinct metabolism to maintain high proliferative rates and resist some cell death signals.⁴⁵ The current work also agreed with Chrzanowska et al.⁴⁶ who elucidated that arginase activity in HCC was lower than in the cirrhotic liver, and the decrease in arginase activity was associated with impaired cirrhotic liver function estimated. On the other hand, Cu-CTAB, GaO-NPs, and Cu-CTAB + GaO-NP complex in the current work showed an increase in arginase activity after administration for DEN groups. This may indicate the potential of Cu-CTAB, GaO-NPs, and Cu-CTAB + GaO-NP complex as anti-proliferative treatments by decreasing the metabolism of tumor cells and consumption of arginine.

Histopathological sections of the liver tissues of the DEN-intoxicated group showed histopathological alterations in the architecture with respect to the control group as focal area of anaplastic hepatocytes with other cells forming acini associated with fibroblastic cell proliferation dividing the degenerated and necrosed hepatic parenchyma into nodules, which is consistent with previous studies.^36,47 While treating DEN-induced HCC rats with Cu-CTAB, GaO-NPs, or Cu-CTAB + GaO-NP complex revealed a degenerative change in the hepatocytes.

There are some limitations that need to be addressed regarding the present study. First of all, the size of the study is limited, and additional large-scale studies are needed to confirm this finding, also power analysis for sample size calculation was not carried out. Secondly, other indicators such as animal weight variations after and before treatment, disease index score, and beside to test the blood index, it is better to provide imaging approaches, such as MRI, US, or others, to monitor the HCC in live rats need to be examined in the further studies to prove the ameliorative effect of the Cu-CTAB + GaO-NP complex. Third, safety study of the Cu-CTAB + GaO-NPs complex should be carried out, and histological analysis must be performed for all the vital organs and compared with control healthy mice to validate our findings. Also, caspase-3 is an apoptotic marker; however, for mitochondrial dysfunction caspase-9 is equally important, thus there is a need to be evaluated together. Finally, toxic effects of Cu-CTAB, GaO-NPs, or Cu-CTAB + GaO-NP complex should be tested in normal cell lines.

Conclusions

To the best of our knowledge, this is the first report in the literature that addresses the ameliorative effect of the novel Cu-CTAB + GaO-NPs complex against DEN-induced HCC in rats. The present study demonstrated that both GaO-NPs and Cu-CTAB + GaO-NP complex exhibit cytotoxic effects against DEN-induced HCC which proved biochemically and histopathologically in in vivo study, while Cu-CTAB + GaO-NP complex exhibited the strongest in vitro anticancer activity against HepG-2, comparable to that of Cu-CTAB and GaO-NPs alone, as proved by in vitro study, which would in turn speculates a possible therapeutic role of the novel Cu-CTAB + GaO-NP complex.

Supplemental Material

Supplemental material - In vitro and in vivo studies of a newly synthesized copper-cetyl tri-methyl ammonium bromide combined with gallium oxide nanoparticles complex as an antitumor agent against hepatocellular carcinoma

Supplemental material for In vitro and in vivo studies of a newly synthesized copper-cetyl tri-methyl ammonium bromide combined with gallium oxide nanoparticles complex as an antitumor agent against hepatocellular carcinoma by Fatma SM Moawed, Riham Abdel-Hamid Haroun, Eman S Abou Zaid, Somya Z Mansour, Abdel-Fattah M Badawi, and Eman I Kandil in International Journal of Immunopathology and Pharmacology.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and material

All data generated or analyzed during this study are included in this published article.

Ethics approval

The present study was approved by the Animal Ethics Care Committee of the National Centre for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority, Cairo, Egypt (approval no. 19A/20). All animal procedures were carried out in accordance with the Ethics Committee of The National Center for Radiation Research and Technology in accordance with the “Guide for the Care and Use of Laboratory Animals” published by the US National Institute of Health (NIH publication, No. 85-23, 1996).

ORCID iD

Riham Abdel-Hamid Haroun

Supplemental Material

Supplemental material for this article is available online.

References

Sung

Ferlay

Siegel

, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.

Wang

Shen

, et al. Dietary fat intake and liver cancer incidence: A population-based cohort study in Chinese men. Int J Cancer 2021; 148(12): 2982–2996. doi: 10.1002/ijc.33507

Connor

Rayner

, et al. Mutational landscape of a chemically-induced mouse model of liver cancer. J Hepatol 2018; 69(4): 840–850. doi: 10.1016/j.jhep.2018.06.009

Farjadian

Ghasemi

Gohari

Roointan

Karimi

Hamblin

. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond) 2019; 14(1): 93–126. doi: 10.2217/nnm-2018-0120

Chitambar

. Medical applications and toxicities of gallium compounds. Int J Environ Res Publ Health 2010; 7(5): 2337–2361. doi: 10.3390/ijerph7052337

Moustafa

Mohamed

Thabet

. Gallium nanoparticle-mediated reduction of brain specific serine protease-4 in an experimental metastatic cancer model. Asian Pac J Cancer Prev 2017; 18(4): 895–903. doi: 10.22034/APJCP.2017.18.4.895

Foster

Clagett-Carr

Hoth

Leyland-Jones

. Gallium nitrate: The second metal with clinical activity. Cancer Treat Rep 1986; 70: 1311–1319.

Pro

Bociek

Chitambar

, et al.

Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin’s lymphoma (NHL) Blood

2004; 104: 682A.

Chitambar

. Gallium-containing anticancer compounds. Future Med Chem 2012; 4(10): 1257–1272. doi: 10.4155/fmc.12.69

10.

Goss

Kaneko

Khuu

, et al. Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. Sci Transl Med 2018; 10(460): eaat7520. doi: 10.1126/scitranslmed.aat7520

11.

Richter

Thomas

Claeys

, et al. A topical hydrogel with deferiprone and gallium-protoporphyrin targets bacterial iron metabolism and has antibiofilm activity. Antimicrob Agents Chemother 2017; 61(6): e00481–e00517. doi: 10.1128/AAC.00481-17

12.

Choi

Britigan

Narayanasamy

. Treatment of virulent mycobacterium tuberculosis and HIV coinfected macrophages with gallium nanoparticles inhibits pathogen growth and modulates macrophage cytokine production. mSphere 2019; 4(4): e00443–e00519. doi: 10.1128/mSphere.00443-19

13.

Bastos

Rossato

Valero

Lagrou

Colombo

Goldman

. Potential of gallium as an antifungal agent. Front Cell Infect Microbiol 2019; 9: 414. doi: 10.3389/fcimb.2019.00414

14.

Betoulle

Etienne

Vernet

. Acute immunotoxicity of gallium to carp (Cyprinus carpio L.) Bull Environ Contam Toxicol 2002; 68: 817–823.

15.

Apseloff

Hackshaw

Whitacre

Weisbrode

Gerber

. Gallium nitrate suppresses lupus in MRL/lpr mice. Naunyn-Schmiedeberg’s archives of pharmacology 1997; 356: 517–525.

16.

Salloum

Brandt

Caride

, et al. Gallium scans in the management of patients with Hodgkin’s disease: A study of 101 patients. J Clin Oncol 1997; 15: 518–527.

17.

Tao

Zhu

. The inhibitory effect of CTAB on human osteosarcoma through the PI3K/AKT signaling pathway. Int J Oncol. 2021; 59(1): 42. doi: 10.3892/ijo.2021.5222

18.

Badawi

Zakhary

Morsy

SMI

Sabry

Fouad

Mousa

. Biochemical study on the effect of Metallo-Surfactant and its loaded nano-analogue as anticancer drug. J Am Sci 2012; 8(3): 763–772.

19.

Gurunathan

Kalishwaralal

, et al. Biosynthesis, purification and characterization of silver nanoparticles using Escherichia coli. Colloids Surf B: Biointerfaces 2009; 74(1): 328–335. doi:10.1016/j.colsurfb.2009.07.048

20.

Abdalla

El-Mahdy

ESM

Mansour

Elsonbaty

Amin

. Regulation of Sirtuin-3 and ERK1/2/p38MAPK by the combination Ga nanoparticles/γ-radiation low dosage: An effective approach for treatment of hepatocellular carcinoma. J Genet Eng Biotechnol 2022; 20(1): 93.

21.

Darwish

EL-Boghdady

. Possible involvement of oxidative stress in diethylnitrosamine-induced hepatocarcinogenesis: Chemopreventive effect of curcumin. J Food Biochem 2013; 37(3): 353–361.

22.

Kumar

Clover

. Intraperitoneal co-administration of low dose urethane with xylazine and ketamine for extended duration of surgical anesthesia in rats. Lab Anim Res 2015; 31(4): 174–179.

23.

Yoshioka

Kawada

Shimada

Mori

. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am J Obstet Gynecol 1979; 135(3): 372–376.

24.

Livak

Schmittgen

. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) Method. Methods 2001; 25(4): 402–408.

25.

Piñero

Dirchwolf

Pessôa

. Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells 2020; 9(6): 1370. doi: 10.3390/cells9061370

26.

Valiahdi

Heffeter

Jakupec

, et al. The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. Melanoma Res 2009; 19(5): 283–293. doi: 10.1097/CMR.0b013e32832b272d

27.

Yang

Chitambar

. Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med 2008; 45(6): 763–772. doi: 10.1016/j.freeradbiomed.2008.05.031

28.

Orteca

Pisaneschi

Rubagotti

, et al. Development of a potential gallium-68-labelled radiotracer based on DOTA-curcumin for colon-rectal carcinoma: From synthesis to in vivo studies. Molecules 2019; 24(3): 644. doi: 10.3390/molecules24030644

29.

Merli

Profumo

Bloise

, et al. Indium/gallium maltolate effects on human breast carcinoma cells: In vitro investigation on cytotoxicity and synergism with mitoxantrone. ACS Omega 2018; 3(4): 4631–4640. doi: 10.1021/acsomega.7b02026

30.

Chua

Bernstein

. Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res 2006; 26: 1739–1743.

31.

Wissing

Mendonca

Kim

, et al. Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells. Cancer Biol Ther 2013; 14(5): 401–410. doi: 10.4161/cbt.23759

32.

Abouzed

Althobaiti

Abdelkhlek

, et al. Antitumor and antioxidant activity of S-Methyl methionine sulfonium chloride against liver cancer induced in wistar albino rats by diethyl nitrosamine and carbon tertrachloride. Int J Environ Res Public Health 2021; 18(18): 9726. doi: 10.3390/ijerph18189726

33.

Tripathy

Thakurela

Sahu

, et al. Fatty changes associated with N-Nitrosodiethylamine (DEN) induced hepatocellular carcinoma: A role of sonic hedgehog signaling pathway. Genes Cancer 2020; 11(1–2): 66–82. doi: 10.18632/genesandcancer.203

34.

Uehara

Ainslie

Kutanzi

, et al. Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci 2013; 132(1): 53–63. doi: 10.1093/toxsci/kfs342

35.

Zayed Mohamed

Aly

Moneim El-Mezayen

El-Salamony

. Effect of co-administration of Bee honey and some chemotherapeutic drugs on dissemination of hepatocellular carcinoma in rats. Toxicol Rep. 2019; 6: 875–888. doi: 10.1016/j.toxrep.2019.08.007

36.

Mansour

Abdallah

HMI

Ibrahim

BMM

Hegazy

Esmail

RSE

Abdel-Salam

. The carcinogenic agent diethylnitrosamine induces early oxidative stress, inflammation and proliferation in rat liver, stomach and colon: Protective effect of ginger extract. Asian Pac J Cancer Prev 2019; 20(8): 2551–2561. doi: 10.31557/APJCP.2019.20.8.2551

37.

Ahmed Mobasher

Galal El-Tantawi

Samy El-Said

. Metformin ameliorates oxidative stress induced by diabetes mellitus and hepatocellular carcinoma in rats. Rep Biochem Mol Biol 2020; 9(1): 115–128. doi: 10.29252/rbmb.9.1.115

38.

El-Sonbaty

Kandil

Haroun

RA-H

. Assessment of the antitumor activity of green biosynthesized zinc nanoparticles as therapeutic agent against renal cancer in rats. Biol Trace Elem Res 2023; 201: 272–281. doi: 10.1007/s12011-022-03126-5

39.

Han

H-W

Joe

Jang

, Reduced cytotoxicity of CTAB-templated silica layer on gold nanorod using fluorescence dyes and its application in cancer theranostics, J Ind Eng Chem 2021; 96: 202–212. doi: 10.1016/j.jiec.2021.01.020

40.

El-Sonbaty

Moawed

Kandil

EIM

Tamamm

. Antitumor and antibacterial efficacy of gallium nanoparticles coated by ellagic acid. Dose Response 2022; 20(1): 15593258211068998. doi: 10.1177/15593258211068998

41.

Collery

Keppler

Madoulet

Desoize

. Gallium in cancer treatment. Crit Rev Oncol-Hematol 2002; 42: 283–296.

42.

Schachter

Fabris

Uhrich

Romsted

Sofou

. The Source of Toxicity in CTAB and CTAB-Stabilized Gold Nanorods. New Brunswick, QC, Canada: Rutgers University; Graduate School 2013. doi: 10.7282/T3X63KMS

43.

Ito

Yip

Katz

, et al. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Mol Pharmacol 2009; 76: 969–983. doi: 10.1124/mol.109.055277

44.

Caldwell

Rodriguez

Toque

Narayanan

Caldwell

. Arginase: A multifaceted enzyme important in health and disease. Physiol Rev 2018; 98(2): 641–665. doi: 10.1152/physrev.00037.2016

45.

Xiong

Teng

Botelho

Lau

Woo

. Arginine metabolism in bacterial pathogenesis and cancer therapy. Int J Mol Sci 2016; 17(3): 363. doi: 10.3390/ijms17030363

46.

Chrzanowska

Krawczyk

Barańczyk-Kuźma

. Changes in arginase isoenzymes pattern in human hepatocellular carcinoma. Biochem Biophys Res Commun 2008; 377(2): 337–340.

47.

Kumar

Bhatt

Rahman

, et al. Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: In vitro and in vivo studies. Int J Nanomedicine. 2017; 12: 6747–6758.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.45 MB

In vitro and in vivo studies of a newly synthesized copper-cetyl tri-methyl ammonium bromide combined with gallium oxide nanoparticles complex as an antitumor agent against hepatocellular carcinoma

Abstract

Keywords

Introduction

Methods

Chemicals

Experimental animals

Methods

Chemical studies

Synthesis of cetyl tri-methyl ammonium bromide copper complex

Synthesis of gallium oxide nanoparticles

Synthesis of Cu-CTAB + GaO-NP complex

Characterization of Cu-CTAB + GaO-NP complex

Transmission electron microscopy (TEM)

Evaluation of therapeutic antitumor efficacy of biosynthesized Cu-CTAB + GaO-NP complex

In vitro study

In vivo study

Determination of the Median Lethal Dose (LD50)

Biochemical studies

Experimental Design:

Biochemical investigations

Detection of caspase-3 by quantitative real time PCR (qRT-PCR)

Histopathological examination

Statistical analysis

Results

Characterization of gallium oxide nanoparticles combined with tetrahalocuprate complex

In vitro study (cell viability tests)

In vivo studies

Determination of median lethal dose (LD50) value

Biochemical markers

Histopathological findings

Discussion

Conclusions

Supplemental Material

Supplemental material - In vitro and in vivo studies of a newly synthesized copper-cetyl tri-methyl ammonium bromide combined with gallium oxide nanoparticles complex as an antitumor agent against hepatocellular carcinoma

Footnotes

Declaration of Conflicting Interests

Funding

Availability of data and material

Ethics approval

ORCID iD

Supplemental Material

References

Supplementary Material

Determination of the Median Lethal Dose (LD₅₀)

Determination of median lethal dose (LD₅₀) value